Bristol Myers, Cellares Ink $380M Deal to Boost CAR-T Therapy Production

    Bristol Myers, Cellares Ink $380M Deal to Boost CAR-T Therapy Production

    Apr 22, 2024, 01:01 PM

    Bristol Myers Squibb has signed a significant $380 million agreement with Cellares to enhance the production and supply of CAR-T cell therapies. This partnership aims to extend the reach of these therapies to more patients across the United States, European Union, and Japan. The deal involves Cellares acting as a contract manufacturer to help meet the growing demand for these innovative treatments.

    View original story

    Markets

    Only registered users can request markets

    Browse all stories on DeepNewz

    Visit